Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Koji Takei"'
Autor:
Koji Takei, Erik P Pioro, Fumihiro Takahashi, Stephen Apple, Benjamin Rix Brooks, Jeffrey Zhang, Jonathan S. Katz
Publikováno v:
Muscle & Nerve. 65:180-186
Introduction Phase 3 study MCI186-19 demonstrated less loss of physical function with edaravone versus placebo, as measured by the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score. A 1-point drop in an individual A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fc03e13f12153605f2d0c575f963c75
https://doi.org/10.1002/mus.27467
https://doi.org/10.1002/mus.27467
Autor:
Wendy Agnese, Kikumi Tsuda, Jeffrey Zhang, Koji Takei, Shawn Liu, Jean Hubble, Joseph M Palumbo, Stephen Apple
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 20:421-431
Objectives: The edaravone development program established a study design in which a treatment effect slowing functional loss in amyotrophic lateral sclerosis (ALS) could be documented within a 24-week time frame. This report elucidates the strategic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8a623e1eed367255198ec008cda1c4a
https://doi.org/10.1080/21678421.2019.1599955
https://doi.org/10.1080/21678421.2019.1599955
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18:5-10
The etiology of amyotrophic lateral sclerosis (ALS) is unknown. Oxidative stress may be one of the major mechanisms involved. In vitro and in vivo data of edaravone suggest that it may possess broad free radical scavenging activity and protect neuron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106f3ae28b8fe9fbb800cbde9705af3f
https://doi.org/10.1080/21678421.2017.1353101
https://doi.org/10.1080/21678421.2017.1353101
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18:49-54
Post-hoc analyses of the ALS Functional Rating Scale-Revised (ALSFRS-R) score data, the primary endpoint in the 24-week double-blind placebo-controlled study of edaravone (MCI186-19, NCT01492686), were performed to confirm statistical robustness of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164977b2349de7a17eff750f255c8146
https://doi.org/10.1080/21678421.2017.1361443
https://doi.org/10.1080/21678421.2017.1361443
Autor:
Atsuhiro Kawaguchi, Yoshinobu Nakamaru, Shuji Kinoshita, Joseph Palumbo, Koji Takei, Masayuki Suzuki
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18:80-87
Amyotrophic lateral sclerosis (ALS) affects persons of all races, and there continues to be a need for effective therapies to treat the disease.To compare the pharmacokinetics (PK) of edaravone between Japanese and Caucasian populations.Data from fiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d8d7b46699202e018508865ed88eb6
https://doi.org/10.1080/21678421.2017.1353100
https://doi.org/10.1080/21678421.2017.1353100
Publikováno v:
Thin Solid Films. 582:263-268
We synthesized CuSbS 2 (CAS), CuSbSe 2 (CASe), and their solid solutions by only a mechanochemical process. CAS powder with good crystallinity was obtained by post-heating at 400 and 500 °C. CASe powder with good crystallinity was obtained by post-h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6e0d3f654ac3613c2b5ec39ebf83258
https://doi.org/10.1016/j.tsf.2014.11.029
https://doi.org/10.1016/j.tsf.2014.11.029
Publikováno v:
physica status solidi c. 12:700-703
(Cu1-xAgx)2ZnSnS4 (CAZTS) and (Cu1-xAgx)2ZnSnSe4 (CAZTSe) solid solutions with 0 ≤ x ≤ 1.0 were synthesized. Their crystal structures were analyzed by Rietveld refinement of X-ray diffraction data. The refined lattice constants a of the kesterite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51e69866a870f6a333a59122506b1bed
https://doi.org/10.1002/pssc.201400343
https://doi.org/10.1002/pssc.201400343
Publikováno v:
Amyotrophic lateral sclerosisfrontotemporal degeneration. 18(sup1)
There is an increasing clinical research focus on neuroprotective agents in amyotrophic lateral sclerosis (ALS). However, it is unclear how generalisable clinical study trial results are between different countries and regions.To assess similarities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd9719bd67922e23c14ad9d339708cb
https://pubmed.ncbi.nlm.nih.gov/28872912
https://pubmed.ncbi.nlm.nih.gov/28872912
Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis
Publikováno v:
Amyotrophic lateral sclerosisfrontotemporal degeneration. 18(sup1)
Study MCI186-19 investigated the safety and efficacy of edaravone in the treatment of ALS. The 24-week, double-blind period was followed by a 24-week, open-label, active extension period. Patients originally receiving edaravone continued edaravone (E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8f9311586fdb3b8475d19c4dc2fec1a
https://pubmed.ncbi.nlm.nih.gov/28872916
https://pubmed.ncbi.nlm.nih.gov/28872916
Publikováno v:
Clinical Pharmacokinetics. 49:47-52
Background and Objectives: Colestilan, an anion-exchange resin binding both phosphate and bile-acid anions, is under development for the treatment of hyperphosphataemia and dyslipidaemia, which occur in the majority of end-stage renal disease patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d160b9bb55b0871ab44fa3b6899495
https://doi.org/10.2165/11318120-000000000-00000
https://doi.org/10.2165/11318120-000000000-00000